Acc Offers Guidance On Using Diabetes Drugs For Cv Event Reduction | Latest News RSS feed

Acc Offers Guidance On Using Diabetes Drugs For Cv Event Reduction - Latest News


Updated cholesterol guidelines offer more personalized risk assessment, additional treatment options for people at the highest risk

A special report simultaneously published as a companion to the cholesterol guidelines provides a more detailed perspective about the use of ... and offers cardiovascular accreditation to hospitals an... read more

The Medicines (MDCO) Q3 2018 Results - Earnings Call Transcript

The trial is designed with overwhelming statistical power, more than 99% to demonstrate lowering of major adverse cardiovascular events, and 90% demonstrate a reduction ... the 2018 AHA/ACC Cholestero... read more

New statin guidelines are an improvement, study shows

(Medical Xpress)—New national guidelines can improve the way statin drugs are prescribed to patients at risk for cardiovascular disease ... researchers said, was the use of low-density lipoprotein (LD... read more

Looking for another news?


Eli Lilly Offers Healthy Outlook to Kick Off November

"Revenue growth driven by greater use ... Cardiovascular Events with a Weekly Incretin in Diabetes" (REWIND) study released on Monday showed superior efficacy for Trulicity, a key drug in Lilly's pipe... read more


Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

The results offer ... a 2008 FDA guidance, makers of all T2D therapies were required to conduct large cardiovascular outcomes trials to ensure that the drugs did not cause heart attacks, strokes, or e... read more

Janssen's first-in-class diabetes drug Invokana wins US approval

“Invokana provides patients with type 2 diabetes the option of a once-daily oral therapy that offers improved ... of diabetes drugs ever since GSK's Avandia was found to increase the risk of cardiovas... read more

Precision Medicine: Using Genomic Data to Predict Drug Side Effects and Benefits

In fact, the evidence suggests that such drugs might even offer ... reduction in major cardiac events experienced by people with diabetes who took Victoza® for up to five years. The new study outlines ... read more

Play of Chance Versus Concerns Regarding Dipeptidyl Peptidase-4 Inhibitors: Heart Failure and Diabetes

This article offers a brief overview of heart failure in diabetes ... Both of the SAVOR 9 and EXAMINE 10 trials failed to find CV event reduction in patients with diabetes using DPP-4 inhibitor therap... read more

Regeneron Pharmaceuticals (REGN) Q4 2017 Results - Earnings Call Transcript

There is a known potential risk of arterial thromboembolic events following the intravitreal use of VEGF inhibitors ... did not show any benefit in cardiovascular mortality. So how important do you th... read more

Why is Atherosclerotic Cardiovascular Disease Risk Overestimated by the ACC/AHA Pooled Cohort Equation?

and underascertainment of events failed to explain the overestimation of ASCVD risk by the ACC/AHA risk prediction model. Further efforts are needed to recalibrate the model using contemporary data to ... read more

High blood pressure redefined for first time in 14 years: 130 is the new high

The guidelines ... had a cardiovascular event such as a heart attack or stroke, or is at high risk of heart attack or stroke based on age, the presence of diabetes mellitus, chronic kidney disease or ... read more

CCS sets new guidelines for management of lipid metabolism disorders that affect cholesterol and cause atherosclerosis

The Canadian Cardiovascular ... used drugs like statins. The guidelines update evidence-based guidance for cardiologists and other clinicians regarding which patients will benefit from statin therapy. ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us